Charles Schwab’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.09M | Buy |
295,041
+12,260
| +4% | +$45.5K | ﹤0.01% | 2871 |
|
|
2025
Q1 | $913K | Sell |
282,781
-25,828
| -8% | -$83.4K | ﹤0.01% | 2873 |
|
|
2024
Q4 | $1.72M | Sell |
308,609
-29,708
| -9% | -$165K | ﹤0.01% | 2727 |
|
|
2024
Q3 | $3.66M | Buy |
338,317
+452
| +0.1% | +$4.89K | ﹤0.01% | 2517 |
|
|
2024
Q2 | $7.09M | Buy |
337,865
+35,660
| +12% | +$749K | ﹤0.01% | 2200 |
|
|
2024
Q1 | $9.63M | Buy |
302,205
+33,567
| +12% | +$1.07M | ﹤0.01% | 2004 |
|
|
2023
Q4 | $5.44M | Buy |
268,638
+10,130
| +4% | +$205K | ﹤0.01% | 2273 |
|
|
2023
Q3 | $3.29M | Sell |
258,508
-7,569
| -3% | -$96.4K | ﹤0.01% | 2433 |
|
|
2023
Q2 | $4.81M | Buy |
266,077
+47,971
| +22% | +$867K | ﹤0.01% | 2245 |
|
|
2023
Q1 | $3.75M | Buy |
218,106
+1,206
| +0.6% | +$20.7K | ﹤0.01% | 2327 |
|
|
2022
Q4 | $4.82M | Buy |
216,900
+5,958
| +3% | +$132K | ﹤0.01% | 2228 |
|
|
2022
Q3 | $1.7M | Buy |
210,942
+34,841
| +20% | +$280K | ﹤0.01% | 2625 |
|
|
2022
Q2 | $1.23M | Sell |
176,101
-13,510
| -7% | -$94.4K | ﹤0.01% | 2717 |
|
|
2022
Q1 | $2.87M | Buy |
189,611
+5,312
| +3% | +$80.3K | ﹤0.01% | 2525 |
|
|
2021
Q4 | $4.04M | Buy |
184,299
+39,145
| +27% | +$859K | ﹤0.01% | 2451 |
|
|
2021
Q3 | $3.92M | Buy |
145,154
+81,934
| +130% | +$2.21M | ﹤0.01% | 2477 |
|
|
2021
Q2 | $1.52M | Buy |
63,220
+5,253
| +9% | +$127K | ﹤0.01% | 2800 |
|
|
2021
Q1 | $2.52M | Buy |
+57,967
| New | +$2.52M | ﹤0.01% | 2599 |
|